title: Experience of gemcitabine plus oxaliplatin chemotherapy in patients with advanced biliary tract carcinoma.
abstract: BACKGROUND
  The combination gemcitabine-oxaliplatin (GEMOX) is frequently used in patients with advanced biliary tract carcinoma (BTC). However, this is only based on phase II studies performed in selected patients.We assessed the efficacy and safety of the GEMOX regimen in non-selected patients with advanced BTC.
  
  
  METHODS
  All consecutive patients with advanced BTC received the GEMOX regimen in a setting outside a study: gemcitabine 1,000 mg/m(2) on day 1, and oxaliplatin 100 mg/m(2) on day 2, treatment repeated every 2 weeks until progression or unacceptable toxicity.
  
  
  RESULTS
  Forty-four patients were enrolled.
  
  
  RESULTS
  1 complete and 6 partial responses (objective response rate = 16.3%), 18 tumour stabilizations (41.9%, disease control rate = 58.1%), median progression-free survival was 5.0 months and median overall survival was 11.0 months.
  
  
  RESULTS
  grade 3 neuropathy in 4 patients, grade 3 asthenia in 5 patients.
  
  
  CONCLUSIONS
  The GEMOX combination was well tolerated, with a modest activity in non-selected patients with advanced BTC. This regimen should be compared to the new standard gemcitabine-cisplatin combination.
authors.affiliation: Department of Medical Oncology, University Hospital, Lille, France.
authors.forename: Antoine
authors.initials: A
authors.lastname: Hollebecque
authors.forename: Olivier
authors.initials: O
authors.lastname: Bouché
authors.forename: Olivier
authors.initials: O
authors.lastname: Romano
authors.forename: Elodie
authors.initials: E
authors.lastname: Scaglia
authors.forename: Stéphane
authors.initials: S
authors.lastname: Cattan
authors.forename: Philippe
authors.initials: P
authors.lastname: Zerbib
authors.forename: Alexandra
authors.initials: A
authors.lastname: Heurgue
authors.forename: Stéphanie
authors.initials: S
authors.lastname: Lagarde
authors.forename: Christophe
authors.initials: C
authors.lastname: Mariette
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Triboulet
authors.forename: François-René
authors.initials: FR
authors.lastname: Pruvot
authors.forename: Mohamed
authors.initials: M
authors.lastname: Hebbar
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001661:Biliary Tract Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D002277:Carcinoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D009944:Organoplatinum Compounds; D003841:Deoxycytidine